Compare EPAM Systems Inc (EPAM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EPAM Systems Inc vs ResMed Inc. — how do they compare? EPAM Systems Inc trades at $87.42 (market cap $4.49B), while ResMed Inc. trades at $202.52 (market cap $28.80B). The key difference: ResMed Inc. is far larger — about 6.4× EPAM Systems Inc's market cap, and ResMed Inc. pays a 1.21% dividend while EPAM Systems Inc pays none. Which is the better fit depends on your goals.
| EPAM | RMD | |
|---|---|---|
Market Cap | $4.49B | $28.80B |
Sector | Technology | Health |
52-Week High | $221.40 | $293.73 |
52-Week Low | $76.04 | $182.82 |
Enterprise Value | $3.74B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EPAM Systems trades at $88.59, up 4.84% today, with a bearish technical signal but strong fundamentals including a P/E of 12.35 and P/S of 0.86. Recent earnings beats and a consensus analyst price target of $128.55 suggest undervaluation, while cash flow trends show operational strength despite a net decline in 2026 projections. The stock faces headwinds from AI sector volatility but benefits from strategic partnerships and AI-native revenue growth.
The outlook for EPAM is cautiously optimistic, with significant upside potential based on analyst targets, though risks include competitive pressures and macroeconomic uncertainty. Investment opportunity lies in its valuation discount and digital engineering expertise, but investors should monitor execution on AI initiatives and sector sentiment shifts for near-term direction.
ResMed (RMD) trades at $201.44, up 4.37% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bearish technical signals but maintains robust fundamentals with 27.44% net margins and consistent revenue growth from $3.6B in 2022 to $5.15B in 2025. Recent strategic moves include divesting MatrixCare for $490M to sharpen focus on core sleep and respiratory care markets.
RMD presents a compelling growth story with analyst consensus pointing to 28% upside potential to $245.88. However, technical weakness and competitive pressures in the medical device space warrant caution. The company's strong cash flow generation and dividend payments provide shareholder value, but investors should monitor execution risks from the business portfolio restructuring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About EPAM Systems Inc
EPAM Systems Inc provides software product development and digital platform engineering services to clients located around the world. The company services include Software Product Development, Custom Application Development, Application Testing, Enterprise Application Platforms, Application Maintenance, and Support and Infrastructure Management. The company focuses on innovative and scalable software solutions. The company uses industry standard and custom developed technology, tools, and platforms to deliver results to handle business challenges. The company primarily offers its solutions in the following industries: financial services, travel and consumer, software and hi-tech, life sciences and healthcare. The majority of revenue is generated from North American clients.
Read more on EPAM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
